(Q47307197)

English

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

scientific article published on 29 December 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Phase II study of paclitaxel given once per week along with trastuzumab and pertuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

12

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

18

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

19

object named as

Jose Baselga

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

Maxine Jochelson

object named as

Maxine Jochelson

17

0 references

Mary Ellen Moynahan

object named as

Mary Ellen Moynahan

14

0 references

author name string

Chau Dang

1

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Neil Iyengar

2

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Farrah Datko

3

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Gabriella D'Andrea

4

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Maria Theodoulou

5

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Maura Dickler

6

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Shari Goldfarb

7

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Diana Lake

8

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Julie Fasano

9

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Monica Fornier

10

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Theresa Gilewski

11

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Devika Gajria

13

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Nicola Hamilton

15

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Sujata Patil

16

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Clifford Hudis

20

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

language of work or name

0 references

publication date

29 December 2014

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

33

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

5

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

442-447

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

HER2-directed therapy for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Adjuvant trastuzumab in HER2-positive breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Weekly paclitaxel in the adjuvant treatment of breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Trastuzumab--mechanism of action and use in clinical practice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

23 May 2018

The safety of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel with trastuzumab in HER-2/neu overexpressed/amplified breast cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

14 August 2018

Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

14 August 2018

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747317

14 August 2018

Identifiers

10.1200/JCO.2014.57.1745

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

13 January 2018

http://europepmc.org/abstract/PMC/5747317

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47307197&oldid=2151417296"